Direct medical costs of non-alcoholic fatty liver disease in Catalonia at the hospital level: a retrospective multicenter study

References

• Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;24(13):321–350. Jan.
   Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017 Feb 28; 15(1):45.
   PubMed Web of Science ®Google Scholar
• Araújo AR, Rosso N, Bedogni G, et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018 Feb;38(Suppl 1):47–51.
   PubMed Web of Science ®Google Scholar
• Glass LM, Hunt CM, Fuchs M, et al. Comorbidities and Nonalcoholic fatty liver disease: the chicken, the egg, or both? Fed Pract. 2019 Feb;36(2):64–71.
   PubMedGoogle Scholar
• Sociedad Española de Oncología Médica (SEOM). Las Cifras del Cáncer en España 2020 [Cancer figures in Spain 2020]. SEOM; 2020. cited 2020 Oct 10. https://seom.org/publicaciones/el-cancer-en-espanya.com
   Google Scholar
• Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and its management. Nutr Clin Pract. 2020 Feb;35(1):72–84.
   PubMed Web of Science ®Google Scholar
• Aly A, Ronnebaum S, Patel D, et al. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA:a systematic literature review. Hepatol Oncol. 2020 Jul 21;7(3): HEP27.
   PubMed Web of Science ®Google Scholar
• Boursier J, Shreay S, Fabron C, et al. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: analysis of a French national hospital database. EClinicalMedicine 2020 Aug;3(25):100445.
   Google Scholar
• Petta S, Ting J, Saragoni S, et al. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutr Metab Cardiovasc Dis. 2020 Jun 9;30(6):1014–1022.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatol. 2016 Nov;64(5):1577–1586.
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007 Sep-Oct;10(5):326–335.
   PubMed Web of Science ®Google Scholar
• Catalan Agency for Health Quality and Evaluation (AQuAS). Data analytics program for health research and innovation. AQuAS; 2020. cited 2020 Oct 10. https://aquas.gencat.cat/ca/ambits/analitica-dades/padris/
   Google Scholar
• Centers for Disease Control and Prevention (CDC). International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). CDC; 2015. cited 2020 Jul 26. https://www.cdc.gov/nchs/icd/icd9cm.htm
   Google Scholar
• Centers for Disease Control and Prevention (CDC). International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). CDC; 2020. cited 2020 Jul 26. https://www.cdc.gov/nchs/icd/icd10cm.htm
   Google Scholar
• Monterde D, Vela E, Clèries M, et al. Los grupos de morbilidad ajustados: nuevo agrupador de morbilidad poblacional de utilidad en el ámbito de la atención primaria [Adjusted morbidity groups: a new multiple morbidity measurement of use in Primary Care]. Atención Primaria. 2016;48(10):674–682. Spanish.
   PubMed Web of Science ®Google Scholar
• Arias-López C, Rodrigo Val MP, Casaña Fernández L, et al. Validación del poder predictivo de los Grupos de Morbilidad Ajustada (GMA) respecto de otras herramientas de estratificación de la población [Validity of predictive power of the adjusted morbidity groups (AMG) with respect to others population stratification tools.]. Rev Esp Salud Publica. 2020 Jul;3(94):e202007079. Spanish.
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Sundararajan V, Quan H, Halfon P, et al. Cross-national comparative performance of three versions of the ICD-10 charlson index. Med Care. 2007 Dec;45(12):1210.
   PubMed Web of Science ®Google Scholar
• Diari Oficial de la Generalitat de Catalunya (DOGC). RESOLUCIÓ SLT/353/2013, de 13 de febrer, sobre la revisió de preus públics corresponents als serveis sanitaris que presta l’Institut Català de la Salut. DOGC núm. 6326-1.3.2013
   Google Scholar
• Diari Oficial de la Generalitat de Catalunya (DOGC). ORDRE SLT/ 71/2020, de 2 de juny, per la qual es regulen els supòsits i conceptes facturables i s’aproven els preus públics corresponents als serveis que presta l’Institut Català de la Salut. DOGC núm 8153-12.6.2020
   Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018 Oct;69(4):896–904.
   PubMed Web of Science ®Google Scholar
• O’Hara J, Finnegan A, Dhillon H, et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep. 2020 Jul 15;2(5):100142.
   PubMedGoogle Scholar
• Gordon SC, Fraysse J, Li S, et al. Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis medicare patients. Am J Gastroenterol. 2020;115(4):562–574. Apr.
   PubMed Web of Science ®Google Scholar
• Miquel M, Clèries M, Vergara M, et al. Economic burden of cirrhosis in Catalonia: a population-based analysis. BMJ Open. 2018 Mar 3; 8(3):e018012.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014 Jul 22;11(7):e1001680.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):32–42.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018 Feb;68(2):335–352.
   PubMed Web of Science ®Google Scholar
• Labenz C, Huber Y, Michel M, et al. Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany. Dig Dis Sci. 2020 Jul;65(7):2112–2119.
   PubMed Web of Science ®Google Scholar
• Kaps L, Labenz C, Galle PR, et al. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterol J. 2020 Oct;8(8):942–948.
   PubMed Web of Science ®Google Scholar
• Labenz C, Huber Y, Michel M, et al. Nonalcoholic fatty liver disease increases the risk of anxiety and depression. Hepatol Commun. 2020 Jun 22;4(9):1293–1301.
   PubMed Web of Science ®Google Scholar
• Report of the project of stratification of the population in GMA groups in the national health system (2014–2016). [Informe del proyecto de Estratificación de la Población por Grupos de Morbilidad Ajustados (GMA) en el Sistema Nacional de Salud (2014–2016)]. Spanish Ministry of Health, 2018
   Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association. Hepatology 2012 Jun;55(6):2005–2023.
   PubMed Web of Science ®Google Scholar
• Geran L, Thomas B, Tully P, et al. Comparability of ICD-10 and ICD-9 for mortality statistics in Canada. Surveys and statistical programs, 2005.
   Google Scholar
• Cano-Serral G, Perez G, Borrell C, COMPARA Group. Comparability between ICD-9 and ICD-10 for the leading causes of death in Spain. Rev Epidemiol Sante Publique. 2006 Sep;54(4):355–365.
   PubMed Web of Science ®Google Scholar